Background Oral oxybutynin has been associated with the development of cognitive impairment. Objective The objective of this study was to describe the use of oral oxybutynin versus other antimuscarinics (e.g., tolterodine, darifenacin, solifenacin, trospium, fesoterodine, transdermal oxybutynin) in older adults with documented cognitive impairment. Methods This is a population-based retrospective analysis of antimuscarinic new users aged C 66 years from January 2008 to December 2011 (n = 42,886) using a 5% random sample of Medicare claims linked with Part D data. Cognitive impairment was defined as a diagnosis of mild cognitive impairment, dementia, use of antidementia medication, and memory loss/drug-induced cognitive conditions in the year prior to the initial antimuscarinic claim. We used multivariable generalized linear models to assess indicators of cognitive impairment associated with initiation of oral oxybutynin versus other antimuscarinics after adjusting for comorbid conditions. Results In total, 33% received oral oxybutynin as initial therapy. Cognitive impairment was documented in 10,259 (23.9%) patients prior to antimuscarinic therapy. Patients with cognitive impairment were 5% more likely to initiate another antimuscarinic versus oral oxybutynin (relative risk [RR] 1.05; 95% confidence interval [CI] 1.03-1.06). The proportion of patients with cognitive impairment initiated on oral oxybutynin increased from 24.1% in 2008 to 41.1% in 2011. The total cost of oral oxybutynin, in $US, year 2011 values, decreased by 10.5%, whereas the total cost of other antimuscarinics increased by 50.3% from 2008 to 2011. Conclusion Our findings suggest opportunities for quality improvement of antimuscarinic prescribing in older adults, but this may be hampered by cost and formulary restrictions.
Introduction
Overactive bladder (OAB) is a condition that can negatively affect the quality of life of older adults. The prevalence of OAB increases with age, and the condition includes signs and symptoms such as urinary frequency, urgency, nocturia, and incontinence, which affect up to 25% of adults aged C 60 years [1] [2] [3] [4] [5] . After non-pharmacological options have failed, the standard treatment for OAB is an antimuscarinic agent or a beta-3 agonist (e.g., mirabegron). In general, various agents have similar efficacy in improving OAB symptoms [6] . However, certain antimuscarinics may cause drug-associated cognitive impairment because they can pass through the blood-brain barrier (e.g., lipophilicity, molecular size, and molecular charge) and block muscarinic-1 receptors (i.e., the receptor responsible for causing cognitive impairment) [4] . Overall, oxybutynin is the most lipophilic antimuscarinic, has the lowest molecular weight, and blocks both muscarinic-1 and muscarinic-3 receptors [4, [7] [8] [9] . This contrasts with darifenacin, which was developed to avoid certain adverse events such as cognitive impairment [10] and is less lipophilic, has a higher molecular weight, and is much more selective to muscarinic-3 receptors (i.e., the receptor responsible for improving OAB symptoms) than is oxybutynin [4, [7] [8] [9] . Eight small prospective studies purported that certain antimuscarinics are associated with an increased risk for worsened cognitive impairment while others are not [11] [12] [13] [14] [15] [16] [17] [18] . Three studies used several different instruments to measure cognition at baseline and after exposure to oral oxybutynin immediate-release (IR), oral oxybutynin extended-release (ER), and comparator agents (e.g., placebo, oxybutynin transdermal, solifenacin, darifenacin) [11] [12] [13] . These studies identified significantly worsened cognition in patients receiving oral oxybutynin IR or oral oxybutynin ER but no change in cognition in patients receiving comparator agents [11] [12] [13] . Two studies that assessed cognition at baseline and after exposure to oral oxybutynin ER showed no worsening of cognition but were limited by their relatively small sample sizes [17, 18] . The other antimuscarinics (e.g., tolterodine, darifenacin, solifenacin, trospium, fesoterodine, transdermal oxybutynin) did not carry a risk for worsened cognition [11] [12] [13] [14] [15] [16] .
Knowledge of the risk profile of medications with similar therapeutic benefits but varying degrees of risk for drug-associated cognitive impairment could lead to differential prescribing of antimuscarinics. Specifically, older adults with cognitive impairment can be preferentially prescribed other antimuscarinics or mirabegron instead of oral oxybutynin to avoid the risk of worsening cognitive impairment when OAB treatment is warranted [11] [12] [13] [14] [15] [16] 19] . However, other antimuscarinics and mirabegron may not be readily available to patients because of formulary restrictions and increased co-payment costs, which may lead to the use of oral oxybutynin in patients with cognitive impairment or the avoidance of treatment in patients with OAB [20] . Understanding the association between cognitive impairment and costs in terms of differential prescribing of antimuscarinics may lead to a better understanding of prescribing behavior for oral oxybutynin versus other antimuscarinics. The aim of this study was to evaluate factors suggestive of documented cognitive impairment with oral oxybutynin versus other antimuscarinics in a general population of older adults.
Methods
We performed a population-based retrospective analysis of older adults in the USA with at least one filled prescription for an antimuscarinic between 1 January 2008 and 31 December 2011 using the 5% random sample longitudinal Medicare claims data from the Chronic Condition Warehouse linked with Part D Prescription Drug Event data. Mirabegron was not included because it was not approved during the study period. This study was approved by the Institutional Review Board of Washington University School of Medicine with a waiver of informed consent.
Study Population
All patients aged C 66 years with at least 12 months of baseline data and complete Medicare Part A (hospital), Part B (physician and outpatient facility), and Part D (prescription drug) coverage prior to the first paid antimuscarinic claim were included. Patients enrolled in a health maintenance organization were excluded because of incomplete claims data.
The following antimuscarinics were identified in the Part D Prescription Drug Event data: oxybutynin, tolterodine, trospium, solifenacin, darifenacin, and fesoterodine. Oral versus transdermal medications and IR versus ER formulations were differentiated. A new-user design was incorporated to include patients who had at least 12 months of coverage prior to their first antimuscarinic claim [21] . Patients were required to have at least one claim for a medication other than an antimuscarinic within 12 months before the first antimuscarinic claim to confirm prescription drug coverage use. Patients who filled two or more different antimuscarinic prescriptions on the date of the first antimuscarinic claim were excluded (n = 44).
Definitions of Antimuscarinic Types
Other antimuscarinics included transdermal oxybutynin (patch or gel), tolterodine IR or ER, trospium IR or ER, solifenacin, darifenacin, and fesoterodine. Oral oxybutynin included both oxybutynin IR (tablet and liquid) and oxybutynin ER (tablet).
Primary Exposure
We hypothesized that documented cognitive impairment through International Statistical Classification of Diseases and Related Health Problems, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for dementia [22] , or memory loss/drug-induced cognitive conditions or use of antidementia medications (e.g., acetylcholinesterase inhibitors and memantine) would result in differential prescribing of oral oxybutynin versus other antimuscarinics. Cognitive impairment was defined as the composite of mild cognitive impairment diagnosis, dementia diagnosis, memory loss/drug-induced cognitive conditions diagnosis [23] , or treatment with an antidementia medication (Appendix 1 in the Electronic Supplementary Material [ESM]).
Factors Potentially Associated with Differential Prescribing of Antimuscarinics
Differential prescribing of oral oxybutynin versus other antimuscarinics on the basis of documented cognitive impairment may also be confounded by comorbid conditions and medications; therefore, we examined several comorbidities using the Elixhauser Comorbidity algorithm [24] , modified to include medications used to treat hypertension, diabetes, and hypothyroidism. We also included other comorbid conditions diagnosed in older adults or comorbid conditions that may be associated with cognitive impairment, along with the medications used to treat these conditions (e.g., osteoporosis, Parkinson's disease, glaucoma, high cholesterol, constipation, weakness, falls). We also assessed medications that may contribute to differential prescribing of antimuscarinics, including antipsychotics, benzodiazepines, and controlled prescriptions used to treat insomnia because providers who prescribed these potentially inappropriate medications in older adults may also be more likely to prescribe oral oxybutynin over other antimuscarinics [25] . We explored patient characteristics, year of the initial antimuscarinic claim, hospitalization in the previous 12 months, and clinic visits to specialist providers (e.g., geriatrician, urologist, neurologist) within 30 days before the first antimuscarinic claim as factors that may influence differential prescribing [26] . All ICD-9-CM diagnosis codes and names of medications used to identify factors of differential prescribing are listed in Appendix 1 in the ESM. Potential factors associated with differential prescribing were collected in the 12 months prior to the first antimuscarinic claim, henceforth referred to as the baseline period [27] . One or two outpatient claims (one claim for acute comorbidities and two claims at least 30 days apart for chronic comorbidities), one inpatient claim, or one medication claim (if specified) were required during the baseline period to be considered as a potential factor for differential prescribing.
Potential Prescribing Cascade
A prescribing cascade occurs when an adverse event of a medication results in the prescription of a new, potentially unnecessary medication, instead of discontinuing the initial medication [28] . The prescribing cascade that results in initiation of an antimuscarinic in patients treated with acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) has been previously described by Gill et al. [29] . Increased urinary symptoms attributable to acetylcholinesterase inhibitors occurred in 4-7% of treated patients [29] [30] [31] but were typically transient [30, 32] . Therefore, we assessed the proportion of patients receiving an acetylcholinesterase inhibitor in the baseline period who initiated or dose-escalated the acetylcholinesterase inhibitor within the 3 months prior to antimuscarinic initiation to further explore the potential for this prescribing cascade.
Influence of Costs
We explored the influence of medication costs, which likely changed over the included years, on antimuscarinic selection in a post hoc analysis. We assessed the median total prescription costs standardized to a 30-day supply. Total prescription costs included the ingredient cost, dispensing fee, and sales tax (when applicable). Costs were adjusted for inflation using the Consumer Price Index for Prescription Drugs standardized to year 2011 values [33] .
Statistical Analyses
Factors during the baseline period that were potentially associated with differential prescribing were compared using descriptive and inferential statistics. Differences between oral oxybutynin and other antimuscarinics in documented cognitive impairment were reported using relative risks (RRs) and p values. RRs were utilized instead of the odds ratio because of the violation of the rare disease assumption [34] . The differences in cognitive impairment by year (i.e., interaction) was assessed to evaluate trends of differential prescribing during the study period.
Factors associated with differential prescribing of oral oxybutynin versus other antimuscarinics were explored using generalized linear models with Proc GENMOD. Generalized linear models were used to calculate RRs in multivariable analysis [35] . Factors, including the interaction with year, with a p value \0.1 were included in the initial multivariable generalized linear models, with variables removed using backward selection. Collinearity was not identified using variance inflation factors. A p value of \0.05 was considered significant in all statistical analyses. Analyses were performed using SAS Enterprise Guide version 7.1. (SAS Institute, Inc., Cary, NC, USA).
Results
From 2008 to 2011, a total of 42,886 patients filled a prescription for an antimuscarinic. Patients were not required to have a diagnosis of OAB (ICD-9-CM diagnosis codes 596.51; 596.59; 788.1x; 788.3x). This is because OAB was likely under-coded as only 38% of patients were coded for OAB in the previous 12 months.
In total, 67% of patients received other antimuscarinics (e.g., tolterodine, trospium, darifenacin, solifenacin, and transdermal oxybutynin) as initial therapy (n = 28,736). Among those who initiated on an antimuscarinic, the proportion of patients treated with oral oxybutynin increased from 24.6% in 2008 to 45.2% in 2011. The most common antimuscarinic used as initial therapy was tolterodine ER, which accounted for 29.6% of all initial antimuscarinic agents (Table 1) . Oxybutynin IR, solifenacin, oxybutynin ER, and darifenacin were the next most commonly utilized initial antimuscarinic: 20.7, 18.4, 12.3, and 9.6% of agents identified, respectively.
Cognitive Impairment and Potential Prescribing Cascade
Overall, 23.9% (n = 10,259) of patients who initiated on an antimuscarinic had documented cognitive impairment prior to antimuscarinic initiation (Table 1) . Among those initiated on an antimuscarinic, 14.8% (n = 6340) of patients had at least one diagnosis code for dementia, 11.2% (n = 4791) of patients had at least one claim for an antidementia medication, and 12.9% (n = 5441) of patients were coded for memory loss/drug-induced cognitive conditions during the baseline period. Among the patients who received an antidementia medication, 27.7% were not coded for dementia during the baseline period (n = 1326). Among patients with cognitive impairment, 30.6% (n = 3140) were initiated on oral oxybutynin and 69.4% (n = 7119) were initiated on another antimuscarinic. Among patients with no cognitive impairment, 33.7% (n = 11,010) were initiated on oral oxybutynin and 66.3% (n = 21,617) were initiated on another antimuscarinic (Appendix 2 in the ESM).
In patients who initiated on oral oxybutynin versus other antimuscarinics, 8.6% (n = 1211) and 10.8% (n = 3097), respectively, were prescribed an acetylcholinesterase inhibitor during the baseline period. Among patients with at least one claim for an acetylcholinesterase inhibitor during the baseline period, a potential prescribing cascade (e.g., initiation or escalation of the acetylcholinesterase inhibitor in the 3 months) occurred in 14.4% (n = 174) and 15.1% (n = 67) of patients prior to initiation of oral oxybutynin versus other antimuscarinic, respectively.
Univariate Analyses
In univariate analyses, several baseline characteristics were associated with the initiation of oral oxybutynin versus other antimuscarinics (Table 2) . Patients with cognitive impairment were 5% more likely to be initiated on another antimuscarinic (RR 1.05; 95% confidence interval [CI] 1.03-1.06). Oral oxybutynin was prescribed less frequently in the early years of the study, with progressively greater use over time. Initiation of oral oxybutynin versus other antimuscarinics also differed significantly by year with respect to cognitive impairment (p = 0.0006) (Fig. 1) . In 2008, patients with and without cognitive impairment were equally as likely to be initiated on another antimuscarinic; by 2011, the RR difference was 7%. Patients with cognitive impairment were 23% less likely in 2011 than in 2008 to be initiated on another antimuscarinic.
Multivariable Analysis
In multivariable analysis, patients with cognitive impairment were progressively less likely to initiate treatment with another antimuscarinic over time after controlling for age, sex, geographic location, ZIP code median household income, high cholesterol, osteoarthritis, osteoporosis, Parkinson's disease, renal failure, vertigo, and the use of sleep medications (Table 3) . Patients without evidence of cognitive impairment were also progressively less likely to initiate treatment with another antimuscarinic over time relative to 2008, and less likely than patients with cognitive impairment to initiate with another antimuscarinic agent after controlling for other variables (Table 3) .
In 2008, the median total prescription cost for oral oxybutynin was $US11.58, which decreased by 10.5% to $US10.36 by 2011 (Fig. 2) . In 2008, the median total prescription cost for another antimuscarinic was $US100.59, which increased by 50.3% to $US151.24 by 2011.
Discussion
This is the first study to examine the association of cognitive impairment among older adults who initiated on oral oxybutynin versus other antimuscarinics. The relationship between cognitive impairment in the baseline period and prescribing of oral oxybutynin versus other antimuscarinics changed over time. Although slightly more patients with cognitive impairment were initiated on another antimuscarinic in each study year, use of the other antimuscarinics decreased progressively over time. If this trend continues, more patients with cognitive impairment treated with an antimuscarinic will initiate oral oxybutynin compared with other antimuscarinics. One likely explanation is drug costs. After standardizing costs to year 2011 values, the total cost of oral oxybutynin decreased slightly over the study period, whereas the total cost of other antimuscarinics increased by 50% over the study period.
We compared the use of oral oxybutynin versus other antimuscarinics based on several studies that suggested oral oxybutynin may be associated with developing/worsening cognitive impairment [11] [12] [13] compared with other antimuscarinics [11] [12] [13] [14] [15] [16] . Suehs et al. [36] used a similar approach to evaluate cognitive impairment and the initiation of antimuscarinics in older adults enrolled in a Medicare Advantage Prescription Drug plan. However, they did not distinguish between the initiation of oral oxybutynin versus other antimuscarinics but instead used an approach informed by the 2012 American Geriatric Society (AGS) Beers Criteria, in which any medication with anticholinergic properties (including all antimuscarinics) was considered potentially inappropriate [37] . Among the studies cited by the AGS Beers Criteria, oral oxybutynin was the only antimuscarinic considered [38] [39] [40] ; therefore, this recommendation regarding cognitive impairment may not be generalizable to other antimuscarinics.
Suehs et al. [36] found that 11.3% of patients treated with an antimuscarinic had been previously diagnosed with dementia and 6.3% treated with an antidementia medication, whereas we found 14.8% had received a diagnosis of dementia and 11.2% had been treated with an antidementia medication. The higher prevalence of dementia and antidementia treatment in our study may be partly because we used a fee-for-service Medicare population, which is generally older than those on a Medication Advantage plan [41] . These differences may also be because Suehs et al. [36] required continuous enrollment for 12 months following the index date, which would have excluded patients with cognitive impairment who died or changed coverage within 1 year following the index date. In addition, our Variables with p value C 0.1: Demographic information (race); Elixhauser Comorbidity Index (congestive heart failure, paralysis, chronic pulmonary disease, diabetes mellitus, depression); other comorbidities (aspiration pneumonia, cardiovascular disease, constipation, delirium, dysphagia, falls, skin ulcer, syncope, traumatic brain injury, weakness), medications (benzodiazepine, stimulant medication), variables associated with cognitive impairment (mild cognitive impairment, memory loss/drug-induced cognitive conditions), provider types (geriatrics), hospitalizations (hospitalized during baseline period) overall prevalence of cognitive impairment may have been higher than that in Suehs et al. [36] because we incorporated diagnosis codes for memory loss in our definition of cognitive impairment [23] . Our study identifies an opportunity for improved antimuscarinic prescribing in older adults with cognitive impairment, as these patients should avoid agents potentially more likely to worsen cognitive impairment. Many approaches can be used to improve the quality of antimuscarinic prescribing in patients with cognitive impairment. Alerts in the electronic medical record or in community pharmacy drug-interaction packages may improve prescribing [42] . A pharmacist can first assess the potential for a prescribing cascade, in which increased urinary symptoms due to an acetylcholinesterase inhibitor are potentially misidentified and the patient initiated on an antimuscarinic [28, 29] . However, this adverse event typically resolves by itself within days or weeks of initiation or dose escalation. We found that approximately 15% of patients with a paid claim for an acetylcholinesterase inhibitor during the baseline period had initiated or dose escalated in the 3 months prior to initiation of an antimuscarinic, regardless of whether it was oral oxybutynin or another antimuscarinic. However, it is likely that a smaller proportion of these patients' symptoms were attributable to the acetylcholinesterase inhibitor given the B 7% incidence of this symptom [29] [30] [31] . If an acetylcholinesterase inhibitor was initiated or the dose escalated in the previous 3 months according to prescription fill history, the pharmacist should speak with the patient and consider contacting the provider to see whether symptoms predate the initiation of the acetylcholinesterase inhibitor; if they did not, then the patient could be educated to not take the antimuscarinic and see whether symptoms resolve on their own. If the addition of the acetylcholinesterase inhibitor does not appear to be related to a prescribing cascade, a community pharmacist can be alerted to the prescribing of oral oxybutynin in a patient treated with an antidementia medication. In this case, a pharmacist can contact the provider to recommend another antimuscarinic or beta-3 agonist that is less likely to worsen cognitive impairment. In our study, 43% of patients with cognitive impairment initiated on oral oxybutynin could have been identified in a community pharmacy setting based on a claim for an antidementia medication in the previous year. This suggests that a pharmacist-directed intervention could make an impact. However, the trend for increased use of oral oxybutynin may also be driven by formulary restrictions and copayment costs. The initially prescribed antimuscarinic may not be the same as that dispensed, because switching to a less expensive or formulary-preferred medication may have occurred following provider approval. As many other antimuscarinics or mirabegron may not be available to patients because of formulary restrictions and increased copayment costs [20] , patients may have to choose between oral oxybutynin-which risks worsening cognition-or no treatment, which may result in sequelae such as falls, depression, or reduced quality of life due to untreated OAB [43] [44] [45] [46] [47] [48] [49] . Moreover, mirabegron, a beta-3 agonist that improves OAB symptoms without blocking antimuscarinic receptors, may theoretically be a better option than other antimuscarinics; however, medication formularies and costs may mean mirabegron will be difficult to afford for many patients after other antimuscarinics become generic. Research on oral oxybutynin versus other antimuscarinics in patients with cognitive impairment is needed to assess whether the costs of other antimuscarinics are offset by downstream costs (e.g., due to differential impacts on cognition), which would provide support for the use of other antimuscarinics or mirabegron over oral oxybutynin in these patients.
This study also has limitations. Since we used claims data, we were unable to capture clinical information such as severity of dementia; however, we controlled for variables that may have acted as proxies for aging and cognitive impairment. Second, fesoterodine (2008) and oxybutynin gel (2009) were not approved until after the beginning of the study period. However, since fesoterodine accounted for only 2.9% and oxybutynin gel 1.2% of new antimuscarinic users in 2011, the impact of the approval during the study period on our results is likely minimal. Third, although we explored different types of specialty providers that may influence differential prescribing, we were unable to confirm whether a specialty provider was the specific prescriber for an antimuscarinic prescription. Fourth, we did not include more recently approved medications for OAB such as mirabegron and onabotulinumtoxinA (a third-line treatment option) because they were not approved or were unavailable for OAB during the study period. However, we would anticipate the differential prescribing of these medications to be similar to that of other antimuscarinics, as mirabegron and onabotulinumtoxinA are not associated with cognitive impairment [50, 51] . Fifth, the potential exists for misclassification due to delayed coding for cognitive impairment following antimuscarinic initiation; however, there is no way to differentiate a delayed coding of cognitive impairment with the development of cognitive impairment potentially due to the antimuscarinic. Sixth, although we included the diagnosis of mild cognitive impairment and memory loss along with dementia as part of the definition for cognitive impairment, the potential exists for undercoding of mild or early symptoms of cognitive impairment in which treatment with other antimuscarinics would be preferred, thus underestimating the number of individuals with baseline cognitive impairment. Undercoding of dementia diagnosis is also likely, as 28% of patients with no dementia diagnosis in the previous year received an antidementia medication during the baseline period. Seventh, no diagnosis codes cover non-pharmacological options, which is firstline treatment for OAB; therefore, we were unable to determine whether patients trialed these options before initiating an antimuscarinic. Despite these limitations, this study does have strengths. Using the 5% sample of Medicare prescription drug claims, this study is generalizable to the US fee-for-service older adult population.
Conclusions
Using medication claims and diagnosis codes, we identified small differential prescribing between oral oxybutynin and other antimuscarinics in older adults with cognitive impairment. Most patients with baseline cognitive impairment who were prescribed an antimuscarinic appropriately received a different antimuscarinic. However, we found an increasing trend of initial therapy using oral oxybutynin correlated with antimuscarinic costs from 2008 to 2011. This finding suggests quality improvement opportunities exist with regards to antimuscarinic prescribing in the older adult population with OAB. Interventions to initiate patients with cognitive impairment on other antimuscarinics or mirabegron instead of oral oxybutynin may require policy changes because of differential costs and current formulary restrictions. Our study documents the need for quality improvement with regards to antimuscarinic prescribing in older adults, as an increasing proportion of oral oxybutynin in patients with cognitive impairment could contribute to worsening of cognitive impairment.
